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Background: Scale-up of triple-drug antiretroviral therapy (ART) in
Africa has transformed the context of childbearing for HIV-positive
women and may impact pregnancy incidence in HIV programs.
Methods: Using observational data from 47,313 HIV-positive
women enrolled at 26 HIV clinics in Kenya and Uganda between
2001 and 2009, we calculated the crude cumulative incidence of
pregnancy for the pre-ART and on-ART periods. The causal effect
of ART use on incident pregnancy was assessed using inverse
probability weighted marginal structural models, and the relationship
was further explored in multivariable Cox models.
Results: Crude cumulative pregnancy incidence at 1 year after
enrollment/ART initiation was 4.0% and 3.9% during the pre-ART
and on-ART periods, respectively. In marginal structural models,
ART use was not signiﬁcantly associated with incident pregnancy
[hazard ratio = 1.06; 95% conﬁdence interval (CI): 0.99 to 1.12].
Similarly, in Cox models, there was no signiﬁcant relationship
between ART use and incident pregnancy (cause-speciﬁc hazard
ratio: 0.98; 95% CI: 0.91 to 1.05), but effect modiﬁcation was
observed. Speciﬁcally, women who were pregnant at enrollment and
on ART had an increased risk of incident pregnancy compared to
those not pregnant at enrollment and not on ART (cause-speciﬁc
hazard ratio: 1.11; 95% CI: 1.01 to 1.23).
Conclusions: In this large cohort, ART initiation was not
associated with incident pregnancy in the general population of
women enrolling in HIV care but rather only among those pregnant
at enrollment. This ﬁnding further highlights the importance of
scaling up access to lifelong treatment for pregnant women.
Key Words: pregnancy incidence, ART, HIV/AIDS, sub-Saharan
Africa
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INTRODUCTION
The massive expansion of HIV prevention, care, and
treatment services in sub-Saharan Africa over the past decade
has transformed the context of childbearing for women living
with HIV in the region. HIV-positive women are living
longer, healthier, and more productive lives1–3 and, for the
ﬁrst time since the start of the epidemic, face a real
opportunity of bearing HIV-negative children.4,5 Whether
and how these new realities impact pregnancy incidence
among women enrolled in HIV programs have important
implications for the organization of services and the clinical
management of women’s health.
Although numerous qualitative and quantitative studies
suggest that women on antiretroviral therapy (ART) are
reconsidering their pregnancy desires in favor of childbear-
ing,6–9 far less is known about the relationship between ART
initiation and incident pregnancy. To date, only 2 studies have
directly examined whether ART initiation alters pregnancy
incidence.6,10 Both found that women on ART were more
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likely to experience incident pregnancy than women in pre-
ART care but suffered from limited generalizability—the ﬁrst
comprised women who were pregnant at enrollment in HIV
care or recently postpartum, and enrolled through prevention
of mother-to-child transmission (PMTCT) programs, and the
second was limited to a single site in a large African city.
Additionally, although these studies provided insights into
patient-level factors associated with incident pregnancy,
information is needed on whether site-level factors (eg,
availability of PMTCT services, location of family planning
services) are associated with incident pregnancy.
We used data from a large sample of women of
reproductive age receiving HIV services in diverse settings
in Kenya and Uganda to estimate the potential inﬂuence of
ART initiation on the incidence of pregnancy. In addition to
offering more generalizable results than previous studies
and examining the potential relationship between site-level
factors and incident pregnancy, the methods used in this
article account for 3 critical factors that directly affect
estimation of pregnancy incidence: (1) the propensity to
initiate ART, and the resulting longitudinal confounding
when examining the causal relationship between ART use
and incident pregnancy; (2) prevalent pregnancy (ie,
pregnancy at enrollment in HIV care) as a factor associated
both with the likelihood of enrollment in HIV care and the
likelihood of ART initiation; and (3) the competing events
of death and loss to program, both of which occur
frequently among patients newly enrolling in care.
METHODS
Study Design and Study Population
We conducted an observational cohort analysis using
patient- and site-level data from the East African regional
consortium of the International Epidemiologic Databases to
Evaluate AIDS collaboration (IeDEA; www.iedea.org). Patient
information routinely collected during clinic visits was docu-
mented by clinicians on national or clinic-developed clinical
encounter forms, entered into on-site databases by data clerks,
and transmitted to the IeDEA East African Regional Data
Center. We evaluated data from women aged 15 to 49 years not
known to have been sterilized or to have had a hysterectomy,
who enrolled in HIV care between November 27, 2001 and
May 8, 2009, and who made at least 1 clinic visit after
enrollment or, if pregnant at enrollment, after delivery. The
exact date of database closure differed by site and ranged from
March 2008 to May 2009. Site-level data were obtained
through a closed-ended facility survey completed by facility
staff in late 2009 and were assumed to apply to the entire study
period.11 The survey documented the context in which facilities
operate and speciﬁc services available at each facility. Use of
these data for research purposes was approved by institutional
review bodies at participating clinics and universities.
Data Management
The study outcome, ﬁrst incident pregnancy, was
deﬁned as the ﬁrst pregnancy observed for women who were
not pregnant at enrollment in HIV care or the ﬁrst subsequent
pregnancy observed for women who were pregnant at
enrollment. Conception dates were used to determine if the
incident pregnancy occurred in the pre-ART or on-ART
period and were estimated using several pregnancy-related
measures available in the databases, including: (1) estimated
gestational age at clinic visit (based on physical examination);
(2) date of last menstrual period (LMP); (3) estimated or
actual date of delivery; and (4) pregnancy status at each clinic
visit. When a gestational age was available, the date of
conception was calculated by backdating the date at which the
pregnancy was detected by the recorded gestational age.
When no gestational age was available but a date of delivery
was recorded, the pregnancy was assumed to have been
carried to term and conception was estimated as occurring
280 days earlier. When neither a gestational age nor a date of
delivery was available but a date of LMP was recorded,
conception was calculated as occurring 14 days after the
LMP. Finally, when only the woman’s pregnancy status was
recorded at 1 or more visits, we assumed a median gestational
age of 147 days at ﬁrst detection and backdated the date of
conception accordingly. The median gestational age of 147
days was based on the gestational age at pregnancy identi-
ﬁcation among women in facilities that recorded gestational
age and/or LMP.
Our primary exposure of interest was therapeutic ART
use. ART was deﬁned as triple therapy and was treated as
a time-dependent variable in all analyses to account for
different levels of risk before and after ART initiation for any
given patient. Women were considered eligible for ART
based on the criteria that were in place at the time of treatment
initiation. Women who initiated triple-therapy ART for
PMTCT, discontinued it after delivery and later became
pregnant again were classiﬁed as not on ART at the time of
conception. Body weight, World Health Organization (WHO)
stage, and CD4 count were among the other patient-level
variables of interest in our analyses and subject to missing
values. Missing weight, WHO stage, and CD4 count across
all visits were imputed by linear interpolation (when 2 values
were available) or by carrying forward the last available value
(when interpolation was impossible). After these procedures,
the proportion of women missing weight, WHO stage, and
CD4 count was ,2%.
Analysis
Pregnancy-free survival was calculated from enrollment
in HIV care (for women who were not pregnant at enrollment)
or from the estimated or recorded date of delivery (for women
who were pregnant at enrollment in HIV care) until: (1) the
time of conception of the ﬁrst incident pregnancy or (2) the
time of the last clinic visit recorded before database closure.
Censoring was a result of transfer, death, or loss to follow-up
(LTFU); the latter was deﬁned as patients without evidence of
transfer or death and with no visits for at least 12 months
before database closure for pre-ART patients and 6 months
for patients on ART. The crude cumulative incidence of
pregnancy and 95% conﬁdence intervals (CIs) were calcu-
lated using the nonparametric estimation method of Aalen and
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Johansen,12 with death and LTFU considered as competing
events. This approach is preferable to using the complement
of the Kaplan–Meier survival estimate or any other model that
considers death and LTFU as censoring events because such
estimates are upwardly biased; indeed, they do not allow
deaths before pregnancy and consequently anticipate addi-
tional pregnancies in the death and LTFU groups.13,14 The
pre-ART cumulative incidence of pregnancy was calculated
censoring data at the time of ART initiation. The on-ART
cumulative incidence of pregnancy was estimated considering
women “at risk” for an incident pregnancy only during the
time since ART initiation (left-truncated data).
We assessed the causal effect of ART on pregnancy
using stabilized inverse probability weighted marginal struc-
tural models that adjusted for potential longitudinal con-
founding because of initiation of ART. In other words, these
models account for the fact that ART may be initiated
differentially for various patient subgroups over time, and
the very membership in these subgroups may be associated
with the likelihood of incident pregnancy. A generalized
estimating equation model with a logit link was used to
generate the estimated probability of starting ART based on
a number of patient-level predictive factors recorded at
enrollment and over time, including CD4 count, WHO stage,
body weight, pregnancy status, the time of each clinic visit
relative to enrollment (expressed as both a linear and
a quadratic trend), and the HIV program where the patient
was receiving services [the Academic Model Providing
Access to Healthcare (AMPATH), www.ampathkenya.org;
the MTCT-Plus Initiative, www.icap.columbia.edu; the Infec-
tious Diseases Institute, and Family AIDS Care and Educa-
tion Services (FACES) Partnership, www.faces-kenya.org].
To examine the robustness of our ﬁndings, we compared
results from the marginal structural model including all
patients to a model that only included women who were
pregnant at enrollment in care. Stabilized inverse probability
weights were determined following the methods of Cole and
Hernán (see Tables S1 and S2, Supplemental Digital Content,
http://links.lww.com/QAI/A795).15
As a secondary approach, we conducted an
unweighted analysis using unadjusted and multivariable
Cox proportional hazard models. Although these are not
causal models in the strict sense, we include them to allow
“backward compatibility” with previous publications.6,10
Patient-level measures of interest included age and preg-
nancy status at enrollment, enrollment year, and WHO
stage, and CD4 count recorded at enrollment and over time.
Regarding site-level factors, we included program model,
facility location (rural, semi-urban, urban), facility type
(teaching/referral hospitals, district hospitals/sub-district
hospitals, rural health centers), location of PMTCT services
(integrated within the HIV clinic, elsewhere in facility, at
another facility), and location of family planning services
(integrated within the HIV clinic, elsewhere in the facility).
For the multivariable analysis, factors signiﬁcant at a = 0.20
level in unadjusted analyses were added to a model that
included ART using a forward stepwise approach and were
evaluated for their effect on the risk of incident pregnancy
and their confounding effect with ART initiation. We also
included an interaction term to determine whether the
relationship of ART and incident pregnancy was modiﬁed
by pregnancy status at enrollment in care. Factors signiﬁ-
cant at a = 0.05 level were retained in the multivariable
model. In the context of the competing risk framework, this
model, which censors death and LTFU, estimates cause-
speciﬁc hazard rates (CSHR).16
Analyses were conducted using SAS 9.2 (SAS
Institute, Cary, NC). Interpolation and imputation of
missing data were performed with STATA version 13.0
(Stata Corp, College Station, TX).
RESULTS
Patient and Site Characteristics
Overall, 47,313 women enrolled in HIV care during the
study period and met the study eligibility criteria, 10% of
whom were pregnant at enrollment (Table 1). Most (86%)
were enrolled between 2005 and 2009. At enrollment, women
averaged 32.5 years and about one-third were known to be
married or living with a partner. Only 4% of women were
known to be nulliparous at enrollment, and among those with
information on prior births, median parity was 3. Approxi-
mately one-third of patients were enrolled with a WHO stage
of III/IV and the median CD4 count at enrollment (assessed
among 83% of women) was 230 cells per microliter
(interquartile range: 99–418). Sixty-one percent of women
had initiated ART by the end of the observation period, such
that 39% of the women were observed only during the pre-
ART period, 8% were observed only on ART, and 53% were
observed both before and after ART initiation.
Table 2 shows site-level characteristics of included
facilities. Women received care in 26 facilities: 23 in Kenya
and 3 in Uganda. Eighteen facilities were part of the
AMPATH Consortium, 3 were afﬁliated with the MTCT-
Plus Initiative, 4 were from the FACES Partnership, and the
remaining site was not afﬁliated with a larger program
model. Half of the facilities were located in urban areas.
Thirteen offered family planning services within the HIV
care clinic. PMTCT services were integrated in the HIV
clinic in 13 facilities.
Crude Cumulative Incidence of Pregnancy
The cumulative incidence of pregnancy at 1 year from
enrollment was 7.0%. The incidence 1 year after enrollment
for those in pre-ART care was 4.0% and 1 year after ART
initiation for those on ART was 3.9% (Table 3). The
cumulative incidence of pregnancy for both the pre-ART
and the on-ART periods was highest for women aged 20
years or younger (pre-ART: 8.7%, 95% CI: 6.8 to 11.0; on
ART: 9.7%, 95% CI: 6.5 to 14.4) and those who were
married or living with a partner (pre-ART: 7.4%, 95% CI:
7.0% to 7.9%; on ART: 5.3%, 95% CI: 4.8% to 6.0%) and
had baseline CD4 counts $350 cells per microliter (pre-
ART: 9.1%, 95% CI: 8.6% to 9.7%; on ART: 6.0%, 95%
CI: 4.9% to 7.2%). Additionally, the cumulative incidence
of pregnancy was higher at 1 year in the pre-ART period
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than in the on-ART period for all subgroups examined, with
the exception of the following: nulliparous women, women
with low CD4 counts at enrollment (#199 cells/mL), and
women enrolled at facilities that referred women off-site for
PMTCT services.
Factors Associated With Incident Pregnancy
Table 4 shows results from the: (1) marginal structural
model weighted for the propensity of ART initiation; (2)
unadjusted Cox models; (3) adjusted Cox model; (4)
adjusted Cox model with the addition of the interaction
term for pregnancy status at enrollment and ART status. The
marginal structural model showed a nonsigniﬁcant associa-
tion between ART use and incident pregnancy (adjusted
hazard ration [aHR]: 1.06, 95% CI: 0.99 to 1.12) (column 1).
ART use was associated with an 11% lower hazard of
incident pregnancy in the unadjusted Cox model (column 2),
but no difference was observed after adjustment for other
patient-level and site-level variables (CSHR: 0.98, 95% CI:
0.91 to 1.05) (column 3). The addition of an interaction term
between pregnancy status at enrollment in HIV care and
time-dependent ART status (column 4) showed that the
relationship between ART use and incident pregnancy was
modiﬁed by pregnancy status at enrollment. Relative to
women who were not pregnant at enrollment and not on
ART, no signiﬁcant difference was observed in the hazard of
pregnancy among women who were not pregnant at
enrollment and on ART, whereas women who were pregnant
at enrollment and not on ART were signiﬁcantly less likely
to have an incident pregnancy (adjusted cause-speciﬁc
hazard ratio [aCSHR]: 0.78, 95% CI: 0.61 to 0.98). ART
use among women who enrolled when pregnant was
associated with an 11% higher hazard of a subsequent
pregnancy compared to women who were not pregnant
when enrolled and not on ART (aCSHR: 1.11, 95% CI: 1.01
to 1.23). The sensitivity analysis that used a marginal
structural model to examine the relationship between ART
use and incident pregnant only among women who were
pregnant at enrollment yielded a hazard ratio = 1.31 (95%
CI: 0.92 to 1.86).
Regarding other patient-level factors independently
associated with incident pregnancy in the adjusted Cox model
TABLE 1. Sociodemographic and Clinical Characteristics of
Study Participants*
n (%)
No. participants 47,313 (100.0)
Age at enrollment, yr
Median, IQR 32.5 (27.6–38.6)
Enrollment year
2001–2004 6403 (13.5)
2005–2006 20,997 (44.4)
2007–2009 19,913 (42.1)
Civil status
Never married/not living with partner 3749 (7.9)
Married/living with partner 15,187 (32.1)
Divorced/separated 5292 (11.2)
Widowed 8381 (17.7)
Missing 14,704 (31.1)
Number of live births
Median, IQR 3.0 (2.0–5.0)
0 1698 (3.6)
1–2 12,724 (26.9)
3–4 11,277 (23.8)
$5 9242 (19.5)
Missing 12,372 (26.2)
Pregnant at enrollment
Yes 4487 (9.5)
No 42,826 (90.5)
Weight at enrollment, kg
Median (IQR) 54.0 (47.5–61.0)
WHO stage at enrollment
I/II 26,278 (55.5)
III/IV 16,330 (34.5)
Missing 4705 (9.9)
CD4 cells per microliter at enrollment
Median (IQR) 230.0 (99–418)
0–99 9789 (20.7)
100–199 7812 (16.5)
200–349 8816 (18.6)
$350 12,713 (26.9)
Missing 8183 (17.3)
Initiated ART during study period
Yes 28,652 (60.6)
No 18,661 (39.4)
*Data do not reﬂect imputed values.
TABLE 2. Site Characteristics
n (%)
Number of sites 26 (100.0)
Country
Kenya 23 (88.0)
Uganda 3 (12.0)
Program
AMPATH 18 (69.2)
MTCT-plus 3 (11.5)
Infectious Diseases Institute 1 (3.9)
FACES 4 (15.4)
Facility location
Urban 13 (50.0)
Semi-urban 7 (26.9)
Rural 6 (23.1)
Facility type
Referral/teaching hospital 4 (15.4)
District hospital 12 (46.2)
Health center 10 (38.5)
Availability of family planning within HIV clinic
Yes 13 (50.0)
No 13 (50.0)
Availability of PMTCT within facility
Embedded in HIV clinic 13 (50.0)
Elsewhere in facility 10 (38.5)
Off-site 3 (11.5)
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TABLE 3. Crude Cumulative Incidence of Pregnancy (and 95% CIs) 1 Year After Enrollment in HIV Care (All Patients), 1 Year After
Enrollment in HIV Care (Pre-ART Patients Only), and 1 Year After ART Initiation (ART Patients Only)
Cumulative Incidence (95% CI)*
Overall Pre-ART Period On-ART Period
Overall 7.9 (7.6 to 8.2) 4.0 (3.8 to 4.2) 3.9 (1.5 to 4.2)
Patient-level characteristics
Age at enrollment, yr
,20 14.2 (11.6 to 17.3) 8.7 (6.8 to 11.0) 9.7 (6.5 to 14.4)
20–29 13.5 (12.9 to 14.2) 9.0 (8.5 to 9.5) 7.0 (6.3 to 7.7)
30–39 6.3 (6.0 to 6.8) 4.1 (3.8 to 4.4) 3.2 (2.9 to 3.6)
40–49 1.4 (1.1 to 1.7) 1.0 (0.8 to 1.2) 0.6 (0.4 to 1.0)
Enrollment year
2001–2004 5.4 (4.8 to 6.0) 3.8 (3.4 to 4.4) 2.5 (1.9 to 3.1)
2005–2006 8.4 (8.0 to 8.8) 5.4 (5.0 to 5.7) 4.4 (4.0 to 4.9)
2007–2009 8.2 (7.7 to 8.7) 5.5 (5.1 to 5.9) 3.6 (3.1 to 4.1)
Education level
None 5.4 (3.9 to 7.4) 3.9 (2.6 to 5.6) 2.4 (1.2 to 4.7)
Primary level 9.8 (9.3 to 10.3) 6.3 (5.9 to 6.7) 4.9 (4.4 to 5.4)
Secondary level 7.3 (6.7 to 7.9) 4.7 (4.3 to 5.2) 3.5 (2.9 to 4.1)
Tertiary level 6.7 (5.5 to 8.2) 4.7 (3.6 to 5.8) 2.8 (1.9 to 4.3)
Civil status
Never married/not living with partner 6.7 (5.7 to 7.9) 4.7 (4.0 to 5.6) 2.7 (1.9 to 3.9)
Married/living with partner 11.5 (10.9 to 12.1) 7.4 (7.0 to 7.9) 5.3 (4.8 to 6.0)
Divorced/separated 6.7 (5.9 to 7.6) 4.1 (3.5 to 4.7) 3.6 (2.8 to 4.5)
Widowed 4.2 (3.7 to 4.7) 2.8 (2.4 to 3.3) 2.0 (1.6 to 2.6)
Number of live births
0 10.1 (8.5 to 12.1) 5.1 (4.0 to 6.4) 6.1 (4.5 to 8.3)
1–2 9.9 (9.3 to 10.6) 6.3 (5.8 to 6.8) 4.8 (4.3 to 5.5)
3–4 9.3 (8.6 to 9.9) 6.0 (5.5 to 6.5) 4.5 (3.9 to 5.2)
$5 5.8 (5.2 to 6.3) 4.1 (3.7 to 4.6) 2.6 (2.1 to 3.2)
Pregnant at enrollment
Yes 14.1 (12.9 to 15.3) 4.6 (4.0 to 5.2) 6.6 (5.8 to 7.6)
No 7.2 (6.9 to 7.5) 5.3 (5.0 to 5.5) 3.4 (3.1 to 3.7)
CD4 cells per microliter at enrollment
0–99 6.2 (5.6 to 6.8) 2.2 (1.9 to 2.5) 3.9 (3.5 to 4.5)
100–199 6.9 (6.3 to 7.5) 3.1 (2.9 to 3.7) 3.7 (3.2 to 4.3)
200–349 7.9 (7.3 to 8.6) 6.2 (5.7 to 6.8) 3.2 (2.5 to 4.0)
$350 11.0 (10.4 to 11.7) 9.1 (8.6 to 9.7) 6.0 (4.9 to 7.2)
Site-level characteristics
Program
AMPATH 8.4 (8.1 to 8.8) 5.5 (5.2 to 5.7) 4.2 (3.8 to 4.5)
MTCT-plus 9.7 (8.1 to 11.6) 7.5 (6.1 to 9.1) 2.7 (2.2 to 3.4)
Infectious Diseases Institute 5.1 (4.6 to 5.8) 3.2 (2.7 to 3.7) 3.2 (1.8 to 5.4)
FACES 7.0 (6.2 to 8.0) 5.3 (4.7 to 6.2) 3.8 (2.7 to 5.4)
Facility location
Urban 8.7 (7.9 to 9.5) 5.8 (5.2 to 6.5) 4.4 (3.6 to 5.3)
Semi-urban 8.1 (7.6 to 8.7) 5.3 (4.9 to 5.8) 4.0 (3.5 to 4.6)
Rural 8.2 (7.8 to 8.7) 5.4 (5.0 to 5.7) 4.2 (3.7 to 4.7)
Facility type
Referral/teaching hospital 7.0 (6.6 to 7.5) 4.6 (4.3 to 5.0) 3.3 (2.9 to 3.7)
District hospital 9.3 (8.7 to 9.9) 6.1 (5.7 to 6.6) 4.4 (3.9 to 5.0)
Health center 7.5 (7.1 to 8.0) 5.0 (4.6 to 5.3) 4.1 (3.6 to 4.7)
Availability of PMTCT within facility
Embedded in HIV clinic 8.4 (7.9 to 8.9) 5.6 (5.2 to 6.0) 4.2 (3.7 to 4.7)
Elsewhere in facility 8.2 (7.7 to 8.7) 5.3 (5.0 to 5.7) 4.1 (3.7 to 4.6)
Off-site 6.6 (4.2 to 0.3) 4.1 (2.1 to 6.9) 4.8 (2.3 to 9.8)
*At 12 months after enrollment (pre-ART period) or 12 months after ART initiation (among women with no previous incident pregnancies who started ART).
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(column 4), patients enrolling in HIV care in 2005–2006
relative to the very early phase of HIV service scale-up
(2001–2004) were more likely to have an incident pregnancy,
whereas those with WHO Stage III/IV vs. I/II were less likely
to experience an incident pregnancy. With respect to site-level
factors, relative to women enrolled at AMPATH, those
enrolled at the Infectious Diseases Institute had a decreased
risk of incident pregnancy, whereas those in the MTCT-Plus
Initiative, most of whom were pregnant at enrollment, had
a signiﬁcantly higher risk of incident pregnancy. In addition,
women enrolled at district/subdistrict hospitals had an
increased risk of incident pregnancy compared to those
TABLE 4. Inverse Probability Weighted, Unadjusted, and Adjusted Hazard of Incident Pregnancy (n = 47,313 Women)
Column 1: Marginal
Structural Model
Weighted for ART
Initiation Propensity
Column 2: Unadjusted
Unweighted Cox
Models
Column 3: Adjusted
Unweighted Cox Model;
No Interaction Term
Column 4: Adjusted
Unweighted Cox Model With
Interaction Term for
Pregnancy Status at Enrollment
in HIV Care and ART Use
aHR 95% CI CSHR 95% CI aCSHR 95% CI aCSHR 95% CI
Patient-level factors
Age at enrollment
(yr, per additional year)
0.90 0.90 to 0.91 0.90 0.90 to 0.91 0.90 0.90 to 0.90 0.90 0.90 to 0.91
Enrollment year
2001–2004 1.00 Reference 1.00 Reference 1.00 Reference
2005–2006 1.19 1.11 to 1.27 1.25 1.15 to 1.36 1.25 1.15 to 1.36
2007–2009 1.14 1.04 to 1.25 1.07 0.96 to 1.20 1.07 0.95 to 1.20
CD4+ (cells/mL) (time dependent)
0–99 1.00 Reference 1.00 Reference 1.00 Reference
100–199 0.98 0.86 to 1.12 0.95 0.83 to 1.09 0.95 0.83 to 1.09
200–349 0.99 0.87 to 1.11 0.90 0.79 to 1.02 0.89 0.78 to 1.02
$350 1.25 1.11 to 1.40 0.90 0.79 to 1.02 0.89 0.78 to 1.01
WHO stage (time dependent)
I/II 1.00 Reference 1.00 Reference 1.00 Reference
III/IV 0.68 0.64 to 0.72 0.81 0.75 to 0.87 0.81 0.76 to 0.87
Weight at enrollment
(kg, per additional 5 kg)
1.00 0.98 to 1.01 0.99 0.98 to 1.01 0.99 0.98 to 1.01
Pregnant at enrollment in HIV care
No 1.00 Reference 1.00 Reference
Yes 1.98 1.83 to 2.13 1.10 0.99 to 1.21
On ART (time dependent)
No 1.00 Reference 1.00 Reference 1.00 Reference
Yes 1.06 0.99 to 1.12 0.89 0.84 to 0.94 0.98 0.91 to 1.05
Pregnancy status at enrollment in
HIV care · ART status
(time-dependent)
Not pregnant at enrollment in
HIV care and not on ART
1.00 Reference
Not pregnant at enrollment in
HIV care and on ART
0.94 0.88 to 1.02
Pregnant at enrollment in HIV
care and not on ART
0.78 0.61 to 0.98
Pregnant at enrollment in HIV
care and on ART
1.11 1.01 to 1.23
Site-level factors
Program
AMPATH 1.00 Reference 1.00 Reference 1.00 Reference
MTCT-plus 1.40 1.25 to 1.57 0.87 0.76 to 1.00 0.92 0.80 to 1.06
Infectious Diseases Institute 0.77 0.71 to 0.83 0.89 0.80 to 0.98 0.90 0.81 to 0.99
FACES 0.90 0.81 to 1.01 0.88 0.73 to 1.07 0.89 0.73 to 1.08
Facility type
Referral/teaching hospital 1.00 Reference 1.00 Reference 1.00 Reference
District/sub-district hospital 1.19 1.11 to 1.27 1.14 1.05 to 1.24 1.15 1.06 to 1.25
Health center 1.00 0.94 to 1.07 1.00 0.92 to 1.09 1.01 0.92 to 1.10
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enrolled at tertiary-level facilities. On-site availability of
PMTCT services and integration of family planning services
in the HIV care clinic were not signiﬁcantly associated with
incident pregnancy in unadjusted or adjusted analyses.
DISCUSSION
In this study, conducted in its entirety before the roll
out of PMTCT option B+, we examined data from a cohort
of 47,313 HIV-positive women at 26 HIV clinics in Kenya
and Uganda and found that the relationship between ART
initiation and incident pregnancy is nuanced and sub-
stantially weaker than previously reported. Whereas the 2
previous studies that included patients both in pre-ART
care and on-ART reported an increased incidence of
pregnancy following ART initiation,6,10 in our study, this
relationship was not observed when we conducted a more
rigorous causal analysis using marginal structural models
and observed only among the subset of women who were
pregnant at enrollment in HIV care in our secondary
analysis that used similar methods to those used in the
previous studies. Of note, one of these earlier studies
comprised women who were pregnant or recently post-
partum at enrollment in HIV care,10 whereas the other did
not examine the potential effect modiﬁcation by baseline
pregnancy status.6 One possible explanation for an
increased likelihood of incident pregnancy while on ART
among women who were pregnant at enrollment in HIV
care is that pregnancies at enrollment represent a large
number of factors that predispose women to both ART
initiation (as pregnant women are more likely to be
identiﬁed by and subsequently enroll in HIV programs)
and incident pregnancy (as women who are pregnant at
enrollment have demonstrated the ability, desire, and/or
availability of the proper environment to get pregnant).
Analyses conducted to generate the weights for the
marginal structural models show that women who were
pregnant at enrollment were substantially more likely to be
initiated on ART than women who were not pregnant at
enrollment (see Tables S1 and S2, Supplemental Digital
Content, http://links.lww.com/QAI/A795). Additionally,
women who were pregnant at enrollment in HIV care
may have received PMTCT services during their previous
pregnancy and thus have increased knowledge of the
prevention beneﬁts of ART, which in turn may have
affected their subsequent pregnancy intentions. Indeed,
HIV-positive women in Zambia who knew of PMTCT
drugs and believed they were effective were more likely
to desire children than HIV-positive women without
such knowledge.17 Taken together, these ﬁndings suggest
that previous analyses may not have adequately adjusted
for the salient effect of prevalent pregnancy in and of
itself on enrollment in care, ART initiation, and
incident pregnancy.
In our study, the crude cumulative pregnancy inci-
dence at 1 year was 4.0% during the pre-ART period and
3.9% during the on-ART period. Although not directly
comparable, the cumulative incidence 1 year after enroll-
ment in the pre-ART period seems lower than the incidence
rate reported by Myer et al10 from a multi-country study
(6.5 per 100 WY), and substantially lower than that
reported from a single site in Kampala, Uganda when
pregnancy tests were used (13.1 per 100 WY).6 Among
patients on ART, more data are available for comparison
and suggest that the cumulative incidence of 3.9% at 1 year
after ART initiation observed in our study is lower than the
incidence rates reported in other studies from Eastern and
Southern Africa, which range from 5.2 to 9.4 per 100 WY
in the absence of pregnancy testing,8,10,18 and is much
lower than that reported when pregnancy testing was used
(21.6–24.5 per 100 WY).6,9 Of note, however, incidence
rates reported in other studies are subject to potentially
signiﬁcant upward bias as they do not take into consider-
ation the competing events of death and LTFU. Pregnancy
incidence rates calculated with our data for the pre-ART
and on-ART periods (8.6 and 6.7 pregnancies per 100 WY,
respectively; data not shown) were substantially higher
than the cumulative pregnancy incidence that we focus on
in this analysis.
With regards to site-level determinants, relative to
the AMPATH Consortium, pregnancy incidence was
lower among patients at the Infectious Diseases Institute,
higher among MTCT-Plus sites, and comparable at
FACES sites. This likely reﬂects differences in program
models. The MTCT-Plus Initiative speciﬁcally targeted
pregnant or recently postpartum women, whereas the
Infectious Diseases Institute is a referral center that does
not speciﬁcally follow pregnant women, and FACES is
a routine clinical care program similar to AMPATH.
Surprisingly, neither the availability of family planning
services within the HIV clinic nor ready access to PMTCT
services within the health facility was associated with
incident pregnancy. This may reﬂect that incident preg-
nancy is largely inﬂuenced by individual characteristics
and behaviors, but it is also possible that the level of
service integration was insufﬁcient to inﬂuence women’s
reproductive behaviors and outcomes. Indeed, a 2013
review of studies examining integration of family planning
and HIV services reported weak implementation of the
intended integration model in the studies from “real-
world” settings,19 and a recent study conducted at one of
the facilities included in our analysis showed that unmet
need for family planning remained high even when
contraceptives were provided in the HIV clinic.20
This study has several important strengths. With data
on nearly 50,000 women with more than 5200 incident
pregnancies in 26 HIV clinics in 2 countries with substantial
HIV epidemics, it is among the largest assessments of the
impact of ART initiation on pregnancy incidence. Addi-
tionally, we used several analytic approaches to assess the
impact of ART initiation on the likelihood of incident
pregnancy, including accounting for longitudinal confound-
ing between factors that are associated with the likelihood
of initiating ART and are affected themselves by exposure
to ART, and examining potential effect modiﬁcation by
pregnancy status at enrollment in HIV care. This multi-
pronged approach provides a more nuanced understanding
of the relationship between ART use and pregnancy
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incidence. We also examined site-level factors associated
with pregnancy incidence, which have not been examined
previously in relation to incident pregnancy but have been
found to be important determinants of other patient out-
comes in HIV clinics.21–24
Several limitations should also be noted. First, we
lacked data on pregnancy desires, which was an important
predictor of incident pregnancy among women enrolled in
HIV care in a previous analysis.6 Similarly, marital status
and parity, important predictors of fertility in the general
population, were unavailable for many patients in our
study and could not be included in models examining
predictors of incident pregnancy. However, inclusion of
pregnancy status at enrollment in HIV care allowed us to
account for some potential confounding because of
reproductive history. Additionally, site-level factors were
assessed in 2009 but were assumed to have applied to the
entire period extending from 2001 to 2009. Given the
intensive scale-up of HIV services during that period, it is
likely that services became more comprehensive and
integrated over time. For example, clinics that had
integrated PMTCT and HIV care and treatment services
by 2009 may not have had PMTCT services available at all
on-site in 2001. Such misclassiﬁcation may have attenu-
ated the true association between site-level factors and
incident pregnancy. Furthermore, site-level variables did
not assess use or coverage of PMTCT and family planning
services but rather their availability.
CONCLUSIONS
In conclusion, among a large cohort of women
enrolling in HIV care in Kenya and Uganda between
2001 and 2009, we found little evidence that ART
initiation is associated with an increased risk of pregnancy
in the general population of women enrolling in HIV care.
The high incidence of pregnancy we observed both before
and after ART initiation underscores the critical impor-
tance of enhancing access to reproductive health services
for all women in HIV care, regardless of ART status. For
women who wish to avoid or delay pregnancy, this entails
ensuring access to effective contraceptives, whereas for
women who desire children, efforts should focus on
promptly ART initiation. Additionally, given the sizable
number of women who were pregnant at enrollment in our
study, and the elevated risk of incident pregnancy in this
group, our ﬁndings provide further evidence of the
importance of scaling up access to lifelong treatment for
pregnant women. Future research should examine whether
increased access to Option B+ changes patterns of incident
pregnancy among women engaged in HIV care.
ACKNOWLEDGMENTS
The authors are grateful to all patients and staff at
the health facilities included in this analysis: the Academic
Model Providing Access to Healthcare program (AM-
PATH), Eldoret, Kenya; the Family AIDS Care and
Education Service program (FACES), Kisumu, Kenya;
Infectious Disease Institute (IDI), Kampala, Uganda; and
3 sites in Columbia University’s Mother to-Child HIV
Transmission-Plus (MTCT-Plus) Initiative (Nyanza Pro-
vincial Hospital, Kisumu, Kenya; St. Francis/St. Raphael
Hospital, Nsambya, Uganda; and Mulago Hospital,
Kampala Uganda).
REFERENCES
1. Liotta G, Mancinelli S, Nielsen-Saines K, et al. Reduction of maternal
mortality with highly active antiretroviral therapy in a large cohort of
HIV-infected pregnant women in Malawi and Mozambique. PLoS One.
2013;8:e71653.
2. UNAIDS WU. Global Update on HIV Treatment 2013; Results, Impact
and Opportunities. Geneva, Switzerland: WHO; 2013.
3. Murray CJ, Ortblad KF, Guinovart C, et al. Global, regional, and national
incidence and mortality for HIV, tuberculosis, and malaria during 1990-
2013: a systematic analysis for the Global Burden of Disease Study 2013.
Lancet. 2014;384:1005–1070.
4. Sinunu MA, Schouten EJ, Wadonda-Kabondo N, et al. Evaluating the
impact of prevention of mother-to-child transmission of HIV in
Malawi through immunization clinic-based surveillance. PLoS One.
2014;9:e100741.
5. Goga AE, Dinh TH, Jackson DJ, et al. First population-level effective-
ness evaluation of a national programme to prevent HIV transmission
from mother to child, South Africa. J Epidemiol Community Health.
2015;69:240–248.
6. Makumbi FE, Nakigozi G, Reynolds SJ, et al. Associations between HIV
antiretroviral therapy and the prevalence and incidence of pregnancy in
Rakai, Uganda. AIDS Res Treat. 2011;2011:519492.
7. Maier M, Andia I, Emenyonu N, et al. Antiretroviral therapy is associated
with increased fertility desire, but not pregnancy or live birth, among
HIV+ women in an early HIV treatment program in rural Uganda. AIDS
Behav. 2009;13(suppl 1):28–37.
8. Homsy J, Bunnell R, Moore D, et al. Reproductive intentions and
outcomes among women on antiretroviral therapy in rural Uganda:
a prospective cohort study. PLoS One. 2009;4:e4149.
9. Schwartz SR, Mehta SH, Taha TE, et al. High pregnancy intentions and
missed opportunities for patient-provider communication about fertility
in a South African cohort of HIV-positive women on antiretroviral
therapy. AIDS Behav. 2012;16:69–78.
10. Myer L, Carter RJ, Katyal M, et al. Impact of antiretroviral therapy on
incidence of pregnancy among HIV-infected women in Sub-Saharan
Africa: a cohort study. Plos Med. 2010;7:e1000229.
11. Duda SN, Farr AM, Lindegren ML, et al. Characteristics and
comprehensiveness of adult HIV care and treatment programmes
in Asia-Paciﬁc, sub-Saharan Africa and the Americas: results of
a site assessment conducted by the International epidemiologic
Databases to Evaluate AIDS (IeDEA) Collaboration. J Int AIDS Soc.
2014;17:19045.
12. Aalen O, Johansen S. An empirical transition matrix for non-
homogeneous Markov chains based on censored observations. Scand J
Stat. 1978;5:141–150.
13. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks
and multi-state models. Stat Med. 2007;26:2389–2430.
14. Bakoyannis G, Touloumi G. Practical methods for competing risks data:
a review. Stat Methods Med Res. 2012;21:257–272.
15. Cole SR, Hernan MA. Constructing inverse probability weights for
marginal structural models. Am J Epidemiol. 2008;168:656–664.
16. Kalbﬂeisch JD, Prentice RL. The Statistical Analysis of Failure Time
Data. 2nd ed New York, NY: John Wiley and Sons; 2002.
17. Bankole A, Biddlecom AE, Dzekedzeke K, et al. Does knowledge about
antiretroviral therapy and mother-to-child transmission affect the rela-
tionships between HIV status and fertility preferences and contraceptive
use? New evidence from Nigeria and Zambia. J Biosoc Sci. 2014;46:
580–599.
18. Andia I, Kaida A, Maier M, et al. Highly active antiretroviral therapy and
increased use of contraceptives among HIV-positive women during
expanding access to antiretroviral therapy in Mbarara, Uganda. Am J
Public Health. 2009;99:340–347.
J Acquir Immune Defic Syndr  Volume 72, Number 3, July 1, 2016 Antiretroviral Therapy and Incident Pregnancy
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. www.jaids.com | 331
19. Wilcher R, Hoke T, Adamchak SE, et al. Integration of family
planning into HIV services: a synthesis of recent evidence. AIDS.
2013;27(suppl 1):S65–S75.
20. Wanyenze RK, Matovu J, Kamya MR, et al. Fertility desires and unmet
need for family planning among HIV infected individuals in two HIV
clinics with differing models of family planning service delivery. BMC
Womens Health. 2015;15:5.
21. Elul B, Basinga P, Nuwagaba-Biribonwoha H, et al. High levels of
adherence and viral suppression in a nationally representative sample of
HIV-infected adults on antiretroviral therapy for 6, 12 and 18 months in
Rwanda. PLoS One. 2013;8:e53586.
22. Lamb MR, Fayorsey R, Nuwagaba-Biribonwoha H, et al. High attrition
before and after ART initiation among youth (15-24 years of age)
enrolled in HIV care. AIDS. 2014;28:559–568.
23. Nash D, Wu Y, Elul B, Hoos D, El Sadr W; International Center for AC,
et al. Program-level and contextual-level determinants of low-median
CD4+ cell count in cohorts of persons initiating ART in eight sub-
Saharan African countries. AIDS. 2011;25:1523–1533.
24. Hoffman S, Wu Y, Lahuerta M, et al. Advanced disease at
enrollment in HIV care in four sub-Saharan African countries:
change from 2006 to 2011 and multilevel predictors in 2011.
AIDS. 2014;28:2429–2438.
Elul et al J Acquir Immune Defic Syndr  Volume 72, Number 3, July 1, 2016
332 | www.jaids.com Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
